RT @RichardPAConway: Spiera et al. Sarilumab in refractory PMR (SAPHYR) - Phase 3 RCT. Significant effect of IL-6i. @Rhe
Tweet Content
Spiera et al. Sarilumab in refractory PMR (SAPHYR) - Phase 3 RCT. Significant effect of IL-6i. @RheumNow #ACR22 Abstr#1676 https://t.co/2MS441B8gU https://t.co/jBd7YJKrTs
Links
Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multice…
https://acrabstracts.org/abstract/sarilumab-in-patients-with-relapsing-polymyal…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off